Congratulations to Mammoth Biosciences team for securing a $100M upfront gene-editing collaboration with Regeneron to develop in vivo gene-editing therapies for various tissues beyond the liver→

Mammoth and Regeneron will collaborate on in vivo CRISPR-based gene editing therapies in a deal worth $100 million upfront plus $370 million in milestones per target.

Read More —>